A Patient’s Experience With an RCC Diagnosis

Opinion
Video

Mr. Cesar Fuentes had a kidney tumor surgically removed; lymph node and bone metastases years later led to immune and targeted therapy which have provided significant tumor shrinkage and generally mild, manageable side effects.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Episode 6: Updates on Genitourinary Cancer Therapies from ASCO 2025
      Episode 6: Updates on Genitourinary Cancer Therapies from ASCO 2025
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
      Incentivizing RCC Research Investment Across Lower-Income Countries
      Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
      Identifying Regional Kidney Cancer Needs Via International Collaboration
      Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
      Using Biopsies to Inform Response Characteristics in Kidney Cancer
      Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
      Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
      Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
      Kidney Cancer Research Consortium Efforts May Improve Treatment Outcomes
      An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
      Kidney Cancer Research Program May Play Pivotal Role in Advancing Care
      Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
      Connecting With Congress to Advance Kidney Cancer Research
      Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
      Collaboration and Research Funding Advancements in Kidney Cancer Advocacy
      Related Content
      First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC

      First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC

      Tim Cortese
      June 19th 2025
      Article

      First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.

      Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

      Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

      Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
      May 1st 2025
      Podcast

      Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

      A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

      Machine Learning Approach May Predict Outcomes in RCC

      Kristie L. Kahl
      June 4th 2025
      Article

      A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      April 1st 2025
      Podcast

      A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

      A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

      Outpatient Robotic Partial Nephrectomy Is Safe/Feasible for Renal Tumors

      Roman Fabbricatore
      April 29th 2025
      Article

      A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

      Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

      Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

      Roman Fabbricatore
      April 6th 2025
      Article

      Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.